Postresolution adaptive immunity is dampened in ccr2^−/− mice and with therapeutic depletion of postresolution Ly6c^hi monocyte. Zymosan (0.1 mg) was injected into ccr2^−/− mice after a determination of (A) mesenteric lymph node CD11c⁺ DCs (R1), CD11c⁺/CD11b⁺ Mφs (R2), and CD11b⁺ Mφs (R3), as well as CD3 and CD19 T and B cells on day 9. (B) The corresponding distribution of lymphocyte populations in the peritoneum at the same time point is shown. MC-21 was given to WT mice 3 days after zymosan, and its effect on (C) Ly6c^hi monocyte populations was determined in the blood of naive animals and (D) mesenteric lymph node lymphocyte and Mφs/DCs alongside (E) lymphocytes and Mφs/DCs in the peritoneum day 9 post-zymosan injection (0.1 mg). (F) Reduced inflammation in ccr2^−/− mice bearing a delayed type hypersensitivity reaction is shown. The P value was ≤.05, as determined by ANOVA, followed by the Bonferroni t test or two-tailed Student t test, with data expressed as mean ± SEM for n = 6 mice/group. *P ≤ .05; **P < .01; ***P < .001.